论文信息 - 1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial - 字舞流文

1151MO Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase II trial

B. Milleron | F. Le Pimpec Barthès | J. Mazières | G. Jeannin | M. Wislez | R. Gervais | M. Massiani | V. Westeel | A. Langlais | A. Lavolé | R. Caliandro | J. Assouad | O. Molinier | D. Damotte | T. Egenod | F. Morin | G. Zalcman | L. Brouchet | M. Antoine | O. Carre | A. Lavolé